Impact of highly active antiretroviral drug therapy (HAART) on biochemical, hematologic, atherogenic and anthropometric profiles of human immunodeficiency virus patients at a tertiary hospital in Owo, Nigeria

Bulletin of the National Research Centre

Table 3 Anthropometric indices of HIV-positive patients, HIV-positive patients on antiretroviral drugs and HIV-negative subjects

Age-group	HIV+ve (n = 70)	HAART (n = 70)	HIV−ve (n = 70)
Weight (kg)
16–25	36.91 ± 5.99^a	55.55 ± 5.63^b	54.27 ± 3.00^b
26–35	37.71 ± 6.92^a	56.33 ± 5.83^b	55.07 ± 4.95^b
36–45	40.46 ± 5.93^a	57.92 ± 5.25^b	57.72 ± 5.99^b
46–55	41.70 ± 5.21^a	60.20 ± 4.78^b	57.69 ± 4.95^b
56–65	42.00 ± 9.13^a	59.00 ± 5.48^b	58.30 ± 5.87^b
Height (m)
16–25	1.49 ± 0.07^a	1.49 ± 0.07^a	1.48 ± 0.04^a
26–35	1.50 ± 0.07^a	1.50 ± 0.07^a	1.49 ± 0.07^a
36–45	1.49 ± 0.07^a	1.52 ± 0.07^a	1.52 ± 0.07^a
46–55	1.54 ± 0.05^a	1.54 ± 0.05^a	1.52 ± 0.07^a
56–65	1.56 ± 0.10^a	1.56 ± 0.10^a	1.52 ± 0.07^a
BMI (kg/m²)
16–25	16.55 ± 1.86^a	24.91 ± 0.83^b	24.82 ± 0.40^b
26–35	16.67 ± 1.68^a	25.05 ± 1.02^b	24.80 ± 0.56^b
36–45	17.33 ± 1.44^a	24.88 ± 0.68^b	25.00 ± 0.49^b
46–55	17.60 ± 2.22^a	25.50 ± 0.97^b	24.88 ± 0.89^b
56–65	17.25 ± 2.06^a	24.25 ± 1.26^b	25.30 ± 1.16^b

Results are presented as mean ± SD (n is as indicated). Values sharing a common superscript in a column are not significantly different (p > 0.05)
HAART HIV-positive patients on highly active antiretroviral therapy, HIV+ve HIV-positive patients, HIV−ve HIV-negative subjects